Neoadjuvant immunochemotherapy—a promising strategy for primary pulmonary lymphoepithelioma-like carcinoma
Neoadjuvant immunochemotherapy is a safe and effective approach to reduce the extent of tumor, render unresectable to resectable, and offer an opportunity to receive modified surgery, which may be a promising strategy for patients with PLELC.
Authors
- Jiawei Chen (ORCID: https://orcid.org/0000-0002-0607-6351)
- Shuben Li (ORCID: https://orcid.org/0000-0002-6012-7500)
- Li Liang (ORCID: https://orcid.org/0000-0002-4108-5464)
- Lei Fan (ORCID: https://orcid.org/0009-0006-7338-0384)
- Hongsheng Deng
Institutions
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Hainan General Hospital (CN)
- State Key Laboratory of Respiratory Disease (CN)
- Hainan Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1186/s12957-024-03617-w
- Citations
- 1
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.28